# Citicoline in Ischemic Stroke, a Randomized Trial

Study · id `cardio:ct-nct06210646` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06210646](<https://clinicaltrials.gov/study/NCT06210646>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06210646

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 800 participants.

## Technical summary

Registry record NCT06210646. Randomized; double masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2024-06-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 800 participants (enrolled count; ClinicalTrials.gov record NCT06210646, source copy `cardio:ctgov-nct06210646-2024-09-19`, retrieved 2026-10-26)
- Started: 2022-12-29 (actual) (ClinicalTrials.gov record NCT06210646, source copy `cardio:ctgov-nct06210646-2024-09-19`, retrieved 2026-10-26)
- Primary completion: 2024-06-29 (actual) (ClinicalTrials.gov record NCT06210646, source copy `cardio:ctgov-nct06210646-2024-09-19`, retrieved 2026-10-26)
- Completion: 2024-06-29 (actual) (ClinicalTrials.gov record NCT06210646, source copy `cardio:ctgov-nct06210646-2024-09-19`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06210646, source copy `cardio:ctgov-nct06210646-2024-09-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06210646-2024-09-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Citicoline in Ischemic Stroke, a Randomized Trial
- Condition: Ischemic Stroke
- Intervention (Drug): Citicoline 2000
- Intervention (Drug): citocoline 1000
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

## Provenance

Content hash: 39ae10866a4ef266d406b3ff6fcfafab80e3db7e10272c0259944943c91a1f89
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
